Albumin nanoparticles with predictable size by desolvation procedure

Journal of Microencapsulation

Volumn 29, Issue 2, 2012, Pages 138-146

  Von Storp, B ^a   Engel, A ^a   Boeker, A ^a   Ploeger, M ^a   Langer, K ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

desolvation procedure; human serum albumin; nanoparticles; particle size; polydispersity

Indexed keywords

ACETONE; ALCOHOL; DRUG CARRIER; HUMAN SERUM ALBUMIN; METHANOL; NANOPARTICLE; WATER;

ARTICLE; CELL STRAIN MCF 7; CELL VIABILITY; CHEMICAL MODIFICATION; CYTOTOXICITY; DESOLVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MICROENCAPSULATION; PARTICLE SIZE; ZETA POTENTIAL;

DRUG DELIVERY SYSTEMS; NANOPARTICLES; PARTICLE SIZE; SERUM ALBUMIN; SOLUBILITY;

EID: 84856914715     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.635218     Document Type: Article

References (33)

1. Arnold K, Herrmann A, Pratsch L, Gawrisch K. The dielectric properties of aqueous solutions of poly(ethylene glycol) and their influence on membrane structure. Biochim Biophys Acta, 1985;815:515-18. (Pubitemid 15018448)
2. Bootz A, Vogel V, Schubert D, Kreuter J. Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm, 2004;57:369-75. (Pubitemid 38283717)
3. Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem, 1994;45:153-203. (Pubitemid 24139888)
4. Coester CJ, Langer K, van Briesen H, Kreuter J. Gelatin nanoparticles by two step desolvation - A new preparation method, surface modifications and cell uptake. J Microencapsulation, 2000;17:187-93. (Pubitemid 30135796)
5. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials, 2008;29:1912-19.
6. Dejaeger N, Demeyere H, Finsy R, Sneyers R, Vanderdeelen J, Vandermeeren P, Vanlaethem M. Particle sizing by photon-correlationspectroscopy. Part I: Monodisperse lattices: Influence of scattering angle and concentration of dispersed material. Part Part Syst Char, 1991;8:179-86.
7. Eppler A, Weigandt M, Hanefeld A, Bunjes H. Relevant shaking stress conditions for antibody preformulation development. Eur J Pharm Biopharm, 2010;74:139-47.
8. Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution. Int J Pharm, 2008;349:249-55. (Pubitemid 350299701)
9. Finsy R, Dejaeger N. Particle sizing by photon-correlation spectroscopy. Part II: Average values. Part Part Syst Char, 1991;8:187-93. (Pubitemid 21711357)
10. Finsy R, Dejaeger N, Sneyers R, Gelade E. Particle sizing by photon-correlation spectroscopy. Part III: Mono and bimodal distributions and dataanalysis. Part Part Syst Char, 1992;9:125-37.
11. Finsy R, Deriemaeker L, Dejaeger N, Sneyers R, Vanderdeelen J, Vandermeeren P, Demeyere H, Stonemasui J, Haestier A, Clauwaert J, et al. Particle sizing by photon-correlation spectroscopy. Part IV: Resolution of bimodals and comparison with other particle sizing methods. Part Part Syst Char, 1993;10:118-28. (Pubitemid 23707852)
12. Fu Q, Sun J, Zhang W, Sui X, Yan Z, He Z. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov, 2009;4:262-72.
13. Habeeb AJ, Hiramoto R. Reaction of proteins with glutaraldehyde. Arch Biochem Biophys, 1968;126:16-26.
14. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: Quantitation and particle size dependency. J Pharm Pharmacol, 1990;42:821-6.
15. Kiese S, Papppenberger A, Friess W, Mahler HC. Shaken, not stirred: Mechanical stress testing of an IgG1 antibody. J Pharm Sci, 2008;97: 4347-66.
16. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm, 2003;257:169-80. (Pubitemid 36507043)
17. Li L, Zhao X, Yang C, Hu H, Qiao M, Chen D. Preparation and optimization of doxorubicin-loaded albumin nanoparticles using response surface methodology. Drug Dev Ind Pharm, 2011;37 (10):1170-80.
18. Lin W, Coombes AG, Davies MC, Davis SS, Illum L. Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. J Drug Target, 1993;1:237-43.
19. Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci, 2009;98:2909-34.
20. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther, 2006;317:1246-53. (Pubitemid 43764130)
21. Miele E, Spinelli GP, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed, 2009;4:99-105.
22. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev, 2001;53:283-318. (Pubitemid 32476118)
23. Moghimi SM, Rajabi-Siahboomi AR. Recent advances in cellular, subcellular and molecular targeting. Adv Drug Delivery Rev, 2000;41:129-33. (Pubitemid 30122953)
24. Preuss A, Chen K, Hackbarth S, Wacker M, Langer K, Roder B. Photosensitizer loaded HSA nanoparticles II: In vitro investigations. Int J Pharm, 2011;404:308-16.
25. Scopes RK. 1994. Protein purification: Priciples and practice. 3rd ed. New York: Springer-Verlag.
26. Steinhauser I, Spankuch B, Strebhardt K, Langer K. Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials, 2006;27:4975-83. (Pubitemid 43866920)
27. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J, 2007;9:E128-47.
28. Wacker M, Chen K, Preuss A, Possemeyer K, Roeder B, Langer K. Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties. Int J Pharm, 2010;393:253-62.
29. Wacker M, Zensi A, Kufleitner J, Ruff A, Schutz J, Stockburger T, Marstaller T, Vogel V. A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation. Int J Pharm, 2011;414:225-32.
30. Wartlick H, Spankuch-Schmitt B, Strebhardt K, Kreuter J, Langer K. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J Controlled Release, 2004;96:483-95. (Pubitemid 38553926)
31. Weber C, Coester C, Kreuter J, Langer K. Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm, 2000a; 194:91-102.
32. Weber C, Reiss S, Langer K. Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups. Int J Pharm, 2000b; 211:67-78. (Pubitemid 32008385)
33. Westcott CC. 1978. pH Measurements. New York: Academic Press.